The primary objective of M22-A3 was to establish standardized criteria for manufacturers to validate the performance of commercial QC strains and for laboratories to verify these materials upon receipt. It focused on ensuring that reference strains (e.g., Escherichia coli ATCC 25922, Staphylococcus aureus ATCC 25923) used for daily or weekly QC produce results within acceptable limits (zones of inhibition or MICs) as defined by CLSI M100.
The third CAP survey, conducted in the fall of 2001, evaluated , comprising 32,702,833 plates, tubes, or bottles —a truly massive dataset that gave the standard its statistical backbone. The findings and key changes in M22-A3 include: clsi m22a3 pdf
The M22-A3 update introduced several improvements based on data from the College of American Pathologists (CAP). Clinical & Laboratory Standards Institute | CLSI Expansion of Exempt Media : The document added 27 new media types The primary objective of M22-A3 was to establish
standard defines which microbiological culture media are exempt from routine QC retesting based on extensive industry surveys. Approved 3rd Edition (M22-A3). Requirement: The findings and key changes in M22-A3 include:
The M22 series has a rich history spanning over three decades, reflecting the evolution of laboratory quality control practices.
Mycobacteria, nocardioform, and other actinomycetes are a group of bacteria that pose significant challenges in susceptibility testing. These organisms have complex growth requirements and are often resistant to multiple antimicrobial agents, making susceptibility testing more difficult.